Tag - SURF

Markets

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

BTIG initiated coverage on six companies with “buy” ratings that it believes are undervalued players in the cell therapy space, each developing some variation of autologous CAR-Ts, “off-the-shelf” allogeneic CAR-Ts...

May 17, 2021

Developments

Surface Oncology gets FDA fast track designation for hepatocellular carcinoma

Surface Oncology’s (NASDAQ:SURF) SRF388 received FDA fast track designation for the treatment of hepatocellular carcinoma in patients who have previously been treated with standard therapies. SRF388 is a fully human...

November 11, 2020

Markets

HCW starts Surface Oncology at buy; PT $11

H.C. Wainwright launched coverage of Surface Oncology (NASDAQ:SURF) with a “buy” rating and $11 price target. The stock closed at $6.40 on Sept. 3. Surface is developing cancer therapies targeting checkpoints that...

September 4, 2020

Tag - SURF

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

Surface Oncology gets FDA fast track designation for hepatocellular carcinoma

HCW starts Surface Oncology at buy; PT $11

General

More